Physician profile
Christopher M Mathews
NPI 1134166291
$7,275.36
in general payments reported to CMS, 2019-2025
30 companies · $1,371 in 2025
The $1,371 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,098 · 2020: $669 · 2021: $739 · 2022: $1,355 · 2023: $1,114 · 2024: $929 · 2025: $1,371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,400 · Education: $14.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,400.43 |
| Education | $14.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,022.95 | 2019-2025 | Xifaxan, Plenvu |
| Abbvie INC. | $1,557.98 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $628.58 | 2019-2025 | Entyvio |
| Ardelyx, INC. | $574.70 | 2022-2025 | Ibsrela |
| Janssen Biotech, INC. | $411.97 | 2019-2025 | Tremfya, Stelara, Simponi |
| Celgene Corporation | $235.98 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $184.18 | 2019-2025 | Ocaliva |
| Gilead Sciences, INC. | $178.20 | 2023-2025 | |
| Aimmune Therapeutics, INC. | $176.88 | 2024-2025 | Zenpep |
| Madrigal Pharmaceuticals | $170.18 | 2024-2025 | Rezdiffra, Resmetirom |
| Nestle Healthcare Nutrition INC. | $151.69 | 2021-2023 | |
| Olympus America INC. | $128.42 | 2019-2020 | |
| Celltrion USA INC. | $123.96 | 2024-2025 | Vegzelma |
| Ipsen Biopharmaceuticals, INC | $105.54 | 2025 | Iqirvo |
| Pfizer INC. | $102.27 | 2019-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $88.45 | 2019-2023 | Sutab, Suflave |
| Merck Sharp & Dohme LLC | $70.17 | 2020-2023 | Dificid |
| Regeneron Healthcare Solutions, INC. | $55.62 | 2023-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $55.55 | 2020-2022 | |
| Ferring Pharmaceuticals INC. | $44.15 | 2019-2023 | Rebyota |
| Novo Nordisk INC | $37.89 | 2025 | Wegovy |
| Genzyme Corporation | $34.55 | 2022-2025 | |
| Exact Sciences Corporation | $32.43 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.86 | 2023 | Cyltezo |
| Capsovision, INC. | $16.90 | 2025 | Capsocam Plus |
| Daiichi Sankyo INC. | $15.45 | 2021 | |
| Phathom Pharmaceuticals, INC. | $14.89 | 2025 | Voquezna |
| Lilly USA, LLC | $14.60 | 2024 | Omvoh |
| Allergan, INC. | $13.52 | 2020 | |
| Romark Laboratories, Lc | $9.85 | 2019-2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Mathews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.